https://www.selleckchem.com/products/iwp-4.html
10; 95% CI, 0.88 to 1.38, I = 0%) and children (OR, 0.96; 95% CI, 0.63 to 1.46, I = 0%). Cefoperazone-sulbactam did not differ significantly from comparators in the risks of all-cause mortality (OR, 0.96; 95% CI, 0.58 to 1.58, I = 0%) or common AEs, namely rash, nausea/vomiting, and superinfection. CONCLUSION The clinical efficacy and tolerability of cefoperazone-sulbactam are comparable to those of comparator drugs in the treatment of febrile neutropenia.Endovenous laser ablation (EVLA) and ultrasound-guided foam sclerotherapy (UGFS) hav
Aimer
Commentaire
Partagez
